Operationalizing Implementation Science in Research Projects

Mari-Lynn Drainoni, PhD, MEd Department of Health Policy & Management, BUSPH Section of Infectious Diseases, BUSM Evans Center for Implementation & Improvement Sciences

Overview

- Selecting and using conceptual frameworks to drive projects & activities
- Study 1: Using PARIHS for a formative evaluation project
- Study 2: Using Proctor for a screening project
- Study 3: Using a combined Pronovost 4E and RE-AIM framework for a community health work project

Selecting and Using Conceptual Frameworks

What is a Conceptual Framework?

- An analytical tool that identifies a "set of variables and relationships that should be examined in order to explain the phenomena" (Kitson et al, 2008)
- Used to make conceptual distinctions & organize ideas
- Can usually be shown pictorially or in a diagram

Why Use Frameworks?

- Provide a <u>systematic</u> method for operationalizing, navigating & evaluating the complexities of implementation
 - Offer overall roadmap and directions
 - Help identify study design & how to best answer questions
 - Generalize knowledge about how to implement & sustain interventions across studies, settings & contexts
 - Identify what is needed to replicate successful implementation & ensure sustainability

Selecting Frameworks

- No single framework works for all studies there are <u>better fitting frameworks</u> depending on the problem & question you want to address
- Implementation frameworks are not individual behavior change models – they focus on some level of provider or system & focus on acceptability, adoption, uptake & sustainability

Selecting Frameworks

- Core issues to consider:
 - 1. Goal and type of study
 - 2. Level of construct flexibility
 - 3. Amount of focus on dissemination vs. implementation activities
 - 4. Framework level individual, organization, community, system, policy
 - 5. What are you going to do, implementation strategies
 - 6. How the framework can best guide your learning

Three Examples of Using Frameworks

- Using PARiHS Formative Assessment of Narcan Distribution in the Emergency Department
- Using Proctor The Hepatitis C Testing and Assessment Project (HepCAT)
- 3. Using the Pronovost 4E & RE-AIM Integrated Model (HIV CHW Project)

Study One: Using the PARiHS (Promoting Action on Research Implementation in Health Services) Model for a Formative Assessment of Narcan Distribution in the Emergency Department

Study 1: Using PARiHS for Formative Assessment of Narcan Distribution

The Quality Gap and Evidence-Based Practice

- Narcan (naloxone) can reverse overdose
- Rescue kits available via Project ASSERT (ED "peer" program) 8am-11pm
- Only 8% of patients at risk getting kits
- Expanded initiative and policy to provide 24-hour coverage to ensure all at risk offered narcan. Three models:
 - 1) Project ASSERT
 - 2) outpatient pharmacy prescriptions
 - 3) inpatient pharmacy distribution

Framework: Promoting Action on Research Implementation in Health Services (PARiHS)



Using the PARiHS Model

Mixed method formative evaluation to:

- 1. Examine early results of new policy (8 months)
- 2. Provide in-depth understanding of preliminary results
- 3. Identify barriers & facilitators to success
- 4. Identify improvement strategies if needed

Methods:

- 1. EMR review
- 2. Focus groups & KI interviews linked to PARIHS constructs

Early Results

Still low numbers, extremely low uptake of non-Project ASSERT component



Results Linked to PARiHS Model

Evidence:

belief in effectiveness, little clinical experience, patients not receptive

Facilitation:

style included episodic & didactic training, no creation of partnerships in development or training

Context:

leadership support, multiple resources, lack of consensus regarding ED PH role

Implementation

Study Two: Using the Proctor Model to Examine the Effectiveness and Implementation of the for a Formative Assessment of the Hepatitis C Testing and Assessment Project (HepCAT

Study 2: The Hepatitis C Testing and Assessment Project (HepCAT)

• What is the best strategy to improve HCV screening & testing within primary care in settings with a large proportion of high-risk patients?

➢ Routine birth cohort testing

- Enhanced risk screening with targeted testing for all others
- 3 large CHCs in South Bronx, New York

Framework: Proctor Conceptual Model of Implementation Research



Using the Proctor Model - 1

- Evidence-Based Practice:
 - Getting people at risk for HCV tested; no evidence for routine testing for all (as with HIV)
- Implementation Strategies multiple levels:
 - 1. Organizational (leadership engagement)
 - 2. Group/learning (training & ongoing support methods)
 - 3. Individual provider (primary level of intervention)
- Outcomes primary focus implementation & service
 - 1. Acceptability agreeable, attitudes (qualitative)
 - 2. Adoption willingness to implement (qualitative)
 - 3. Appropriateness perceptions of fit (qualitative)
 - 4. Feasibility can it be done (qualitative)

Using the Proctor Model - 2

- Outcomes primary focus implementation & se
 - Fidelity did they do it (screener & EMR testing data)
 - Penetration % eligible that got it (EMR testing data, screeners done)
 - Sustainability does the intervention stick (EMR testing data post-intervention)
 - Efficiency did the right people get screened/tested (EMR testing data & risk data, screener risk & testing data)
 - Patient-centeredness patient responses (qualitative)
 - Timeliness getting people to care (EMR referrals & linkage)
 - Equity care does not vary by personal characteristics (EMR demographics linked to screener EMR testing data)
 - Symptomatology % tested who tested positive

HepCAT Project Timeline

Baseline Assessment	Months 1-8	Stakeholder engagement (kick-off meeting, site visits); qualitative research activities; chart reviews; EMR data
Develop Materials & Training	Months 9-12	Develop risk screener; site visits; intensive training
Enhanced Risk Screener	Months 13-18	Implement screener; targeted testing; ongoing support & reminders; clinic "champions" and "boosters"; screener data; EMR data
Birth Cohort	Months 19-23	Age based testing with reminder stickers; EMR data
Wrap-up	Months 23-24	Post-intervention qualitative interviews, complete data analyses

Implementation Strategies

- Provider & staff training
- Champions
- Stakeholder engagement activities feedback incorporated into structure (who should screen)
- Resources (staff from study at all sites, study staff put labels on to make intervention easy to do)
- Swag & props (pins, pedometers, laminated cards)
- Boosters & regular meetings

Enhanced Risk Screener Phase

Hepatitis C Scree	ning
History/Risk Factors EVER homeless EVER incarcerated EVER snorted ANY drug EVER injected ANY drug ≥20 lifetime sexual partners Liver disease (told by MD) Chronic Hemodialysis Organ transplant pre-1992 Transfusion pre-1992 Maternal Hepatitis C Labs: Elevated LFT (ALT: F≥ 20, M≥ Country of birth: if US specify PR Other reason for HCV test (specify)	Yes No DK
Plan Recent HCV Test? HCV test ordered? (N/A = HCV+)	Yes No N/A

Birth Cohort Sticker

Hepatitis C Assessment & Testing Project (HepCAT) CDC data show that people born from 1945-1964 (currently ages 45-64) are more likely to have hepatitis C than those in other age groups. At CHCC, FHC, & CFCC, hepatitis C infection is 4 times greater in this age group.

🗆 Yes 🗆 No

Yes
 No

- Is your patient currently aged 45-64?
 If yes, a hepatitis C test is strongly recommended.
- Did you order a hepatitis C test for this patient today?

Screening & Testing over Time



Incremental Value of Screening Items

Factor	#	# tested	% of total	Cumulative
	identified	positive	positives	%
Ever injected drugs	56	17	41.5%	41.5%
Ever snorted drugs	200	6	14.6%	56.1%
Elevated ALT (documented in EMR)	185	4	9.8%	65.9%
Transfusion before 1992	59	3	8.0%	73.1%
20+ lifetime sex partners	115	2	4.9%	78.0%
Maternal hepatitis C	10	1	2.4%	80.5%
Liver diseases (physician diagnosis)	23	1	2.4%	82.9%
Ever homeless	66	0	0.0%	82.9%
Ever incarcerated	67	0	0.0%	82.9%
Chronic hemodialysis	0	0	0.0%	82.9%
Transplant before 1992	0	0	0.0%	82.9%
Total		34		82.9%

Implementation Feedback

- Good reminder to focus on HCV
- Screener increased knowledge about patients
- Screener time-consuming
- General preference for screener
- Birth cohort phase difficult to buy into
- Remaining ambivalence
- Process too difficult and not realistic

Study Three: Using an Integrated Pronovost/RE-AIM for Project to **Examine Using Community** Health Workers to Improve Linkage and Retention in HIV Care

Study 3: Using CHWs for HIV Care

Project Goals:

- 1. Increase utilization of CHWs to improve access, retention & outcomes among PLWH
- 2. Strengthen HIV health care workforce & build capacity of RWHAP recipients to integrate CHWs into care team
- 3. Evaluate implementation & effectiveness of different CHW models

Project Structure & Activities

- 10 RWCA-funded sites across US to be funded to:
 - Implement program with limited funding & limited staffing
 - Receive training
 - Participate in evaluation
- 3 year project
 - 12 months: BU team planning: program, curriculum, training development, evaluation design
 - 18 months: program implementation & evaluation, ongoing training, collect & provide data
 - 6 months: complete evaluation
- Evaluation:
 - No additional funding for surveys or data provision
 - No funding for control/comparison sites

Evaluation

- Hybrid 3 implementation-effectiveness evaluation
 - Primary focus: Experience implementing the programs from multiple staff/organizational perspectives
 - Assessed via:
 - Client, CHW, and site experience with intervention
 - Integration of CHW program into setting
 - Secondary focus: does the intervention work?
 - Assessed via:
 - Changes in clinical markers, adherence, appointment attendance, changes in unmet needs

Pronovost 4 E Process Theory



reminders, and learning from mistakes

Overall concepts

Envision the problem within the larger healthcare system Engage collaborative multidisciplinary teams centrally (stages 1-3) and locally (stage 4)

RE-AIM Framework

Re-AIM Concept	Key Questions for Concept
REACH	Who is expected to benefit? What percent of those are actually exposed to intervention? Who are they (demographics)?
EFFECTIVENESS	What is the impact of the intervention on the proposed outcome (clinical markers, retention, adherence)?
ADOPTION	What settings applied the program? Who applied it?
IMPLEMENTATION	How was the program applied? How consistently was it applied in the way it was intended?
MAINTENANCE	Is the program maintained over time?

Integrated Implementation Model

1. Summarize the evidence

Identify interventions associated with improved outcomes Select interventions with the largest benefit and lowest barriers to use Convert interventions to behaviors

2. Identify local barriers to implementation

Observe staff performing the interventions

"Walk the process" to identify defects in each step of implementation Enlist al stakeholders to share concerns & identify potential gains & losses associated with implementation

3. Measure performance

Select measures (process or outcome) Develop and pilot test measures Measure baseline performance

4. Ensure all patients receive the interventions Process & Program Outcomes: Reach (4Es: Engage & Educate) Number, percent of target audience & demographics Effectiveness Maintenance (4Es: Evaluate) (4Es: Evaluate) Linkage intervention Program sustainability & outcomes & impact on patient effects quality of life & VL Adoption Implementation (4Es: Execute) (4Es: Execute) Representiveness & Methods & delivery of number of settings & linkage interventions clinicians

Overall Concepts

Envision the problem within the larger healthcare system Engage collaborative multidisciplinary teams centrally & locally

Why this Integrated Framework?

- Integrating a process implementation model & evaluative model will help us drive both intervention implementation & evaluation.
- Helps ensure model works for sites & increases their buy-in by maximizing our focus on how the implementation & evaluation should be planned, organized, and scheduled
- Pronovost model well-suited for larger scale projects that include multiple sites with centralized support and TA. Cyclical nature of model allows for formative work & feedback to drive modifications & adaptations
- Pronovost model does not provide clear evaluation methodology. RE-AIM provides ideas for quantitative outcome measurement

Using the Integrated Framework

- Steps 1 3 of Pronovost model will be used to create a single CHW intervention to be evaluated in Step 4.
 - Step 1: summarize the evidence regarding effective CHW programs & transferability to HIV as appropriate
 - Step 2: identify local barriers to implementation
 - Needs assessment
 - Observation: "walk the process" & qualitative methods
 - Step 3: identification of performance measures, pilot
 - Step 4: integrate the 4Es into RE-AIM outcomes
 - Engage and Educate components integrated within the Reach dimension of RE-AIM
 - Evaluate component integrated within Effectiveness and Maintenance components
 - Execute component of integrated within Implementation and Adoption

RE-AIM Framework Outcomes

Dimension	Measure(s)	Data Source(s)
REACH	% eligible who get CHW intervention Dose of intervention received Demographics	Medical chart data Client survey
EFFECTIVENESS	Impact of the intervention on clinical markers, retention, adherence, unmet needs, stigma, self-efficacy, health literacy	Medical chart data Client survey
ADOPTION	Frequency of adoption Where is program adopted	CHW encounter form Site visit tools
IMPLEMENTATION	Specific activities & dose Integration of CHWs into team Adaptions to protocol	CHW encounter form Fidelity monitoring tool CHW satisfaction survey Qualitative interview Site visit tools
MAINTENANCE	Consistency over time Budget impact	CHW encounter form Cost analysis

Acknowledgements

- Collaborators
 - Edward Bernstein
 - Alexander Walley
 - Patricia Mitchell
- Funders
 - Boston University School of Public Health
 - AHRQ
 - -CDC
 - HRSA

Acknowledgements

Sally Bachman Allyson Baughman **Edward Bernstein Cindy Christiansen** Alexander de Groot **Jacqueline Ellison** Haley Falkenberry James Feldman Jane Fox Allen Gifford Elisa Koppelman Alain Litwin Stacia Maher M. Diane McKee

Patricia Mitchell Serena Rajabiun Bryce Smith William Southern Derric Topp Madeline Wachman Alexander Walley Cindy Weinbaum

BUPSH CDC HRSA AHRQ Project Assert